The Significance of the Apelinergic System in Doxorubicin-induced Cardiotoxicity

Overview

Journal Heart Fail Rev

Date 2024 Jul 11

PMID 38990214

Authors

Katarzyna Matusik

Katarzyna Kaminska

Aleksandra Sobiborowicz-Sadowska

Hubert Borzuta

Kasper Buczma

Agnieszka Cudnoch-Jedrzejewska

Affiliations

Soon will be listed here.

Abstract

Cancer is the leading cause of death worldwide, and the number of cancer-related deaths is expected to increase. Common types of cancer include skin, breast, lung, prostate, and colorectal cancers. While clinical research has improved cancer therapies, these treatments often come with significant side effects such as chronic fatigue, hair loss, and nausea. In addition, cancer treatments can cause long-term cardiovascular complications. Doxorubicin (DOX) therapy is one example, which can lead to decreased left ventricle (LV) echocardiography (ECHO) parameters, increased oxidative stress in cellular level, and even cardiac fibrosis. The apelinergic system, specifically apelin and its receptor, together, has shown properties that could potentially protect the heart and mitigate the damages caused by DOX anti-cancer treatment. Studies have suggested that stimulating the apelinergic system may have therapeutic benefits for heart damage induced by DOX. Further research in chronic preclinical models is needed to confirm this hypothesis and understand the mechanism of action for the apelinergic system. This review aims to collect and present data on the effects of the apelinergic system on doxorubicin-induced cardiotoxicity.

References

Dodos F, Halbsguth T, Erdmann E, Hoppe U . Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008; 97(5):318-26. DOI: 10.1007/s00392-007-0633-6. View

Wang X, Zhang L, Feng M, Xu Z, Cheng Z, Qian L . ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK/MAPK and PI3K/AKT signaling pathways. Front Pharmacol. 2022; 13:873614. PMC: 9492932. DOI: 10.3389/fphar.2022.873614. View

Wang M, Gupta R, Rastogi S, Kohli S, Sabbah M, Zhang K . Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail. 2013; 19(7):509-16. PMC: 3706995. DOI: 10.1016/j.cardfail.2013.05.004. View

Moscat J, Diaz-Meco M . p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009; 137(6):1001-4. PMC: 3971861. DOI: 10.1016/j.cell.2009.05.023. View

Chng S, Ho L, Tian J, Reversade B . ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013; 27(6):672-80. DOI: 10.1016/j.devcel.2013.11.002. View

Kidoya H, Takakura N . Biology of the apelin-APJ axis in vascular formation. J Biochem. 2012; 152(2):125-31. DOI: 10.1093/jb/mvs071. View

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

Boengler K, Leybaert L, Ruiz-Meana M, Schulz R . Connexin 43 in Mitochondria: What Do We Really Know About Its Function?. Front Physiol. 2022; 13:928934. PMC: 9289461. DOI: 10.3389/fphys.2022.928934. View

Ewer M, Lippman S . Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005; 23(13):2900-2. DOI: 10.1200/JCO.2005.05.827. View

10.

Dai T, Ramirez-Correa G, Gao W . Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006; 553(1-3):222-8. PMC: 1815301. DOI: 10.1016/j.ejphar.2006.09.034. View

11.

de Oliveira A, Vergara A, Wang X, Vederas J, Oudit G . Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists. Peptides. 2021; 147:170697. DOI: 10.1016/j.peptides.2021.170697. View

12.

Damiani R, Moura D, Viau C, Caceres R, Henriques J, Saffi J . Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016; 90(9):2063-2076. DOI: 10.1007/s00204-016-1759-y. View

13.

Ma K, Gao W, Xu H, Liang W, Ma G . Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome. J Renin Angiotensin Aldosterone Syst. 2022; 2022:3239057. PMC: 8803448. DOI: 10.1155/2022/3239057. View

14.

Azizi Y, Imani A, Fanaei H, Khamse S, Parvizi M, Faghihi M . Post-infarct treatment with [Pyr1]apelin-13 exerts anti-remodelling and anti-apoptotic effects in rats' hearts. Kardiol Pol. 2017; 75(6):605-613. DOI: 10.5603/KP.a2017.0022. View

15.

Minotti G, RONCHI R, Salvatorelli E, Menna P, Cairo G . Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001; 61(23):8422-8. View

16.

Canzoneri J, Oyelere A . Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res. 2008; 36(21):6825-34. PMC: 2588532. DOI: 10.1093/nar/gkn774. View

17.

Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A . Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146(4):1764-71. DOI: 10.1210/en.2004-1427. View

18.

ARCAMONE F, Franceschi G, Penco S, Selva A . Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett. 1969; (13):1007-10. DOI: 10.1016/s0040-4039(01)97723-8. View

19.

Kabir S, Lingappa N, Mayrovitz H . Potential Therapeutic Treatments for Doxorubicin-Induced Cardiomyopathy. Cureus. 2022; 14(1):e21154. PMC: 8833288. DOI: 10.7759/cureus.21154. View

20.

Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V . Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009; 61(1):154-71. DOI: 10.1016/s1734-1140(09)70018-0. View